| |
CDR = 0 (n = 291)
|
CDR = 0.5 (n = 587)
|
CDR = 1 (n = 104)
|
|---|
| |
A-/TN- (n = 122)
|
A+/TN- (n = 52)
|
A+/TN+ (n = 45)
|
A-/TN+ (n = 72)
|
A-/TN- (n = 118)
|
A+/TN- (n = 93)
|
A+/TN+ (n = 282)
|
A-/TN+ (n = 94)
|
A-/TN- (n = 2)
|
A+/TN- (n = 15)
|
A+/TN+ (n = 80)
|
A-/TN+ (n = 7)
|
|---|
|
Age, y
|
72.5 (5.50)
|
73.5 (5.95)
|
76.3 (5.46)
|
74.6 (6.56)
|
69.9 (7.56)
|
72.6 (7.74)
|
73.3 (7.08)
|
73.2 (8.16)
|
89.2 (1.63)
|
76.3 (6.05)
|
74.1 (9.28)
|
79.8 (8.02)
|
|
Female, n (%)
|
58 (47.5)
|
24 (46.2)
|
24 (53.3)
|
40 (55.6)
|
55 (46.6)
|
21 (22.6)
|
119 (42.2)
|
42 (44.7)
|
0 (0)
|
5 (33.3)
|
40 (50.0)
|
2 (28.6)
|
|
APOE ε4 carriers, n (%)
|
17 (13.9)
|
20 (38.5)
|
27 (60.0)
|
15 (20.8)
|
24 (20.3)
|
47 (50.5)
|
216 (76.6)
|
32 (34.0)
|
0 (0)
|
8 (53.3)
|
59 (73.8)
|
1 (14.3)
|
|
Education, y
|
16.4 (2.79)
|
16.0 (2.65)
|
16.5 (2.55)
|
16.4 (2.57)
|
16.0 (2.68)
|
16.1 (2.97)
|
15.9 (2.90)
|
15.9 (2.66)
|
17.0 (0)
|
16.2 (2.51)
|
15.1 (2.80)
|
15.0 (2.08)
|
|
CSF biomarkers, pg/ml*
|
|
T-tau
|
185 (32.2)
|
167 (40.5)
|
332 (79.3)
|
322 (71.9)
|
183.4 (38.2)
|
173 (40.0)
|
381 (136)
|
338 (111)
|
234 (6.08)
|
188 (38.8)
|
393 (136)
|
489 (221)
|
|
P-tau181P
|
16.2 (2.88)
|
15.4 (4.07)
|
33.3 (9.09)
|
28.9 (7.43)
|
15.8 (3.32)
|
15.9 (4.14)
|
38.9 (14.7)
|
31.6 (13.7)
|
19.3 (1.20)
|
17.4 (3.53)
|
39.2 (15.0)
|
43.2 (22.9)
|
|
Aβ1-42
|
1456 (223)
|
723 (196)
|
717 (168)
|
1538 (235)
|
1428 (247)
|
632 (196)
|
634 (168)
|
1427 (290)
|
1330 (14.9)
|
538 (185)
|
570 (159)
|
1484 (290)
|
|
sTREM2
|
3741 (1690)
|
2835 (1524)
|
4839 (2240)
|
5378 (2147)
|
3436 (1754)
|
2791 (1292)
|
4441 (2211)
|
5478 (2370)
|
5660 (2008)
|
3051 (1128)
|
3967 (2000)
|
7619 (3539)
|
- Data are expressed as mean and standard deviation (SD) or number (n) and percentage (%), as appropriate.
- *The CSF core biomarkers measurements were performed using the electrochemiluminiscence immunoassays Elecsys Total-tau CSF, phosphor-tau(181P) CSF and β-amyloid(1-42) CSF, which have an upper technical limit of 1300 pg/ml (T-tau), 120pg/ml (P-tau181P) or 1700 pg/ml (Aβ1-42). The values above these limits were truncated to the respective upper technical limit.
- Abbreviations: A Aβ pathology biomarker status, Aβ1-42 amyloid-β 42, APOE apolipoprotein E, CDR clinical dementia rating, CSF cerebrospinal fluid, N neurodegeneration biomarker status, P-tau181P tau phosphorylated at threonine 181, T tau pathology biomarker status, T-tau total tau, y year
